急性淋巴细胞白血病发病机制和药物研究进展

刘佳; 江振洲; 张陆勇; LIU Jia; JIANG Zhenzhou; ZHANG Luyong

温馨提示：建议您使用Chrome80、火狐74+、IE9+浏览器，当您的浏览器版本过低，可能会影响部分功能正常使用。

主办：天津药物研究院中国药学会

微信公众号

网站二维码

2025年6月4日 4:20 星期三

首页 > 过刊浏览>2019年第42卷第10期 >2019,42(10):2100-2105. DOI:10.7501/j.issn.1674-6376.2019.10.036

急性淋巴细胞白血病发病机制和药物研究进展

刘佳
刘佳
中国药科大学, 江苏省新药筛选重点实验室, 江苏南京 210009
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
江振洲
江振洲
中国药科大学, 江苏省新药筛选重点实验室, 江苏南京 210009
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
张陆勇
张陆勇
中国药科大学, 江苏省新药筛选重点实验室, 江苏南京 210009;广东药科大学新药研发中心, 广东广州 510006
通讯作者.
Email: lyzhang@cpu.edu.cn
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

Pathogenesis and drug development of acute lymphoblastic leukemia

LIU Jia
LIU Jia
Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
JIANG Zhenzhou
JIANG Zhenzhou
Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
ZHANG Luyong
ZHANG Luyong
Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China;Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China
Contact Author.
Email: lyzhang@cpu.edu.cn
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

发布日期：2019-11-05

摘要
图/表
访问统计
PDF预览
参考文献
相似文献
引证文献
附件

[关键词]

急性淋巴细胞白血病 ; 发病机制 ; 基因突变 ; 通路 ; 靶向药物

[摘要]

急性淋巴细胞白血病（Acute lymphoblastic leukemia，ALL）是一种血液性的恶性肿瘤，在成人急性白血病中较为常见。白血病细胞的生物学特征是涉及前体淋巴细胞增殖分化相关的染色体异常和基因改变。尽管联合化疗方法已取得重大进展，但耐药性及复发性仍为治疗的难题，因此就ALL基因方面的机制通路，及靶向治疗药物进行综述，旨在为临床新药研发提供参考。

[Key word]

acute lymphoblastic leukemia ; pathogenesis ; gene mutation ; pathway ; targeted drugs

[Abstract]

Acute lymphoblastic leukemia is a hematological malignant tumor, which is more common in adult acute leukemia. The biological characteristics of leukemic cells are chromosomal abnormalities and genetic alterations related to the proliferation and differentiation of precursor lymphocytes. Although significant progress has been made in combination chemotherapy, medicine resistance and relapse are still difficult problems in treatment. Therefore, the mechanism of ALL gene mutation, pathway and targeted therapy are reviewed in this paper, in order to provide reference for clinical new drug research and development.

[中图分类号]

[基金项目]

引用本文 / Get Citation

刘佳,江振洲,张陆勇.急性淋巴细胞白血病发病机制和药物研究进展[J].药物评价研究,2019,42(10):2100-2105

分享 / Share

文章指标 / Article Metrics

点击次数: 1964

下载次数: 1217

Html阅读次数: 0

引用次数: 0

历史 / History

收稿日期: 2019-03-21

在线发布日期: 2019-11-05

[1] Paul S, Kantarjian H, Jabbour E J. Adult Acute Lymphoblastic Leukemia[J]. Mayo Clinic Proceedings, 2016, 91(11):1645-1666.

[2] Hunger S P, Mullighan C G. Acute lymphoblastic leukemia in children[J]. N Engl J Med, 2015, 373(16):1541-1552.

[3] Malouf C, Ottersbach K. Molecular processes involved in B cell acute lymphoblastic leukaemia[J]. Cell Mol Life Sci, 2018, 75(3):417-446.

[4] Friend B D, Schiller G J. Closing the gap:Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults[J]. Blood Reviews, 2018, 32(2):122-129.

[5] Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia[J]. Pediatrics International, 2018, 60(1):4-12.

[6] Rahmani M, Talebi M, Hagh M F, et al. Aberrant DNA methylation of key genes and acute lymphoblastic leukemia[J]. Biomedicine & Pharmacotherapy, 2018, 97:1493-1500.

[7] Pierro J, Hogan L E, Bhatla T, et al. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia[J]. Expert Review of Anticancer Therapy, 2017, 17(8):725-736.

[8] Tasian S K, Loh M L, Hunger S P. Childhood acute lymphoblastic leukemia:Integrating genomics into therapy[J]. Cancer, 2015, 121(20):3577-3590.

[9] Tan S H, Bertulfo F C, Sanda T. Leukemia-initiating cells in T-cell acute lymphoblastic leukemia[J]. Front Oncol, 2017, 7:218.

[10] Short N J, Jabbour E. Minimal residual disease in acute lymphoblastic leukemia:how to recognize and treat it[J]. Curr Oncol Rep, 2017, 19:6.

[11] Sanchez-Martin M, Ferrando A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia[J]. Blood, 2017, 129(9):1124-1133.

[12] Drobna M, Szarzyńska-Zawadzka B, Dawidowska M. Tcell acute lymphoblastic leukemia from miRNA perspective:Basic concepts, experimental approaches, and potential biomarkers[J]. Blood Reviews, 2018, 32(6):457-472.

[13] Girardi T, Vicente C, Cools J, et al. The genetics and molecular biology of T-ALL[J]. Blood, 2017, 129(9):1113-1123.

[14] Jabbour E, O'Brien S, Konopleva M, et al. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia[J]. Cancer, 2015, 121(15):2517-2528.

[15] Izraeli S, Shochat C, Tal N, et al. Towards precision medicine in childhood leukemia-Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia[J]. Cancer Lett, 2014, 352(1):15-20.

[16] Harrison C J. Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease[J]. Blood, 2015, 125(9):1383-1386.

[17] Marke R, van Leeuwen F N, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia[J]. Haematologica, 2018, 103(4):565-574.

[18] Iacobucci I, Mullighan C G. Genetic basis of acute lymphoblastic leukemia[J]. JCO, 2017, 35(9):975-983.

[19] Hales E C, Taub J W, Matherly L H. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis:Targeted therapy of γ-secretase inhibitor resistant Tcell acute lymphoblastic leukemia[J]. Cellular Signalling, 2014, 26(1):149-161.

[20] Bongiovanni D, Saccomani V, Piovan E. Aberrant signaling pathways in T-cell acute lymphoblastic leukemia[J]. IJMS, 2017, 18(9):1904.

[21] Knoechel B, Bhatt A, Pan L, et al. Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024:genetic and epigenetic findings in an outlier case[J]. Cold Spring Harb Mol Case Stud, 2015, 1(1):a000539.

[22] He Y, Sun L P, Xu Y P, et al. Combined inhibition of PI 3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia[J]. Cancer Letters, 2018, 420:49-59.

[23] Yuan T, Yang Y, Chen J, et al. Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia:a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD[J]. Leukemia, 2017, 31(11):2355-2364.

[24] Adam E, Kim H N, Gang E J, et al. The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of b ALL[J]. Cancers, 2017, 9(12):121.

[25] Cramer S D, Aplan P D, Durum S K. Therapeutic targeting of IL-7R signaling pathways in ALL treatment[J]. Blood, 2016, 128(4):473-478.

[26] Senkevitch E, Hixon J, Li W Q, et al. Abstract 2287:A model system to treat T-cell acute lymphoblastic leukemia with JAK inhibitors[J]. Cancer Res, 2015, 75(15 Supplement):2287.

[27] Vicente C, Schwab C, Broux M, et al. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia[J]. Haematologica, 2015, 100(10):1301-1310.

[28] Gomes A M, Soares M V D, Ribeiro P, et al. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels[J]. Haematologica, 2014, 99(6):1062-1068.

[29] Maude S L, Dolai S, Delgado-Martin C, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia[J]. Blood, 2015, 125(11):1759-1767.

[30] Cheng Z, Yi Y, Xie S, et al. The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAKSTAT signalling and activation of the crosstalk between apoptosis and autophagy signalling[J]. Oncotarget, 2017, 8(63):106753-106763.

[31] Montaño A, Forero-Castro M, Marchena-Mendoza D, et al. New challenges in targeting signaling pathways in acute lymphoblastic leukemia by NGS approaches:an update[J]. Cancers, 2018, 10(4):110.

[32] Irving J A E. Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia[J]. Br J Haematol, 2016, 172(5):655-666.

[33] Mark K, Emma M C D, Merel W, et al. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations[J]. Oncotarget, 2017, 8(9):14835-14846.

[34] Jerchel I S, Hoogkamer A Q, Ariës I M, et al. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia[J]. Leukemia, 2018, 32(4):931-940.

[35] Aries I M, van den Dungen R E, Koudijs M J, et al. Towards personalized therapy in pediatric acute lymphoblastic leukemia:RAS mutations and prednisolone resistance[J]. Haematologica, 2015, 100(4):e132-e136.

[36] Pimentel-Gutiérrez H J, Bobadilla-Morales L, BarbaBarba C C, et al. Curcumin potentiates the effect of chemotherapy against acute lymphoblastic leukemia cells via downregulation of NF-κB[J]. Oncol Lett, 2016, 12(5):4117-4124.

[37] Vázquez-Franco J E, Reyes-Maldonado E, Vela-Ojeda J, et al. Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCRABL positive and BCR-ABL negative acute lymphoblastic leukemia[J]. Leuk Res, 2012, 36(7):862-867.

[38] dos Santos N R, Ghezzo M N, da Silva R C, et al. NF-κb in T-cell acute lymphoblastic leukemia:oncogenic functions in leukemic and in microenvironmental cells[J]. Cancers, 2010, 2(4):1838-1860.

[39] Koyama D, Kikuchi J, Hiraoka N, et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia[J]. Leukemia, 2014, 28(6):1216-1226.

[40] Knaus H, Kanakry C, Luznik L, et al. Immunomodulatory drugs:immune checkpoint agents in acute leukemia[J]. CDT, 2017, 18(3):315-331.

[41] Hoffman L M, Gore L. Blinatumomab, a Bi-specific antiCD19/CD3 BiTEÂ® antibody for the treatment of acute lymphoblastic leukemia:perspectives and current pediatric applications[J]. Front Oncol, 2014, 4:63.

[42] Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017, 376(9):836-847.

[43] Kantarjian H M, DeAngelo D J, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia[J]. N Engl J Med, 2016, 375(8):740-753.

[44] Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia:a comprehensive review and 2017 update[J]. Blood Cancer J, 2017, 7(6):e577.

[45] Pehlivan K C, Duncan B B, Lee D W. CAR-T cell therapy for acute lymphoblastic leukemia:transforming the treatment of relapsed and refractory disease[J]. Curr Hematol Malig Rep, 2018, 13(5):396-406.